ResMed Inc. (RMD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 238.70 |
| Open | 237.07 |
| Bid | 180.00 x 1000 |
| Ask | 246.15 x 800 |
| Day's Range | 235.58 - 241.97 |
| 52 Week Range | 189.40 - 301.34 |
| Volume | |
| Avg. Volume | 578,701 |
| Market Cap | 35.372B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 45.62 |
| EPS (TTM) | 5.30 |
| Earnings Date | Aug 11, 2022 |
| Forward Dividend & Yield | 1.68 (0.69%) |
| Ex-Dividend Date | May 11, 2022 |
| 1y Target Est | 244.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RMD
Related Research
- ResMed Inc.Analyst Report: ResMed Inc.ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.RatingFair ValueEconomic Moat17 days agoMorningstar
- Zacks
NuVasive (NUVA) Lags Q2 Earnings Estimates
NuVasive (NUVA) delivered earnings and revenue surprises of -14.55% and 1.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
ResMed Acquires Leipzig-based mementor with Insomnia Digital Health Solution somnio
Acquisition lays foundation to build ResMed’s digital sleep medicine portfolio in Germanysomnio digital health application focused on improving sleep in patients with diagnosed insomnia, filling care gap and providing alternative to prevailing drug therapy mementor to be integrated into ResMed in Germany as a separate business segment and will serve as a platform for further developments in the field of digital health MARTINSRIED, Germany and LEIPZIG, Germany, Aug. 02, 2022 (GLOBE NEWSWIRE) -- R
- Benzinga
Semiconductor Shortages - See How ResMed Is Tackling
ResMed Inc (NYSE: RMD) has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips. Instead of offering wireless communications capability, the new AirSense 10 "Card to Cloud" models collect the patient's data on an SD card, which can then be mailed to the provider and uploaded to the cloud. Needham notes that ResMed continues to sell its AirSense 10 and AirSense 11 models with cellular connectivity. The AirSense 10 Card to Cloud is now
